• FabiSpray: India launches its first nasal spray to treat adult Covid patients 

    National
    FabiSpray: India launches its first nasal spray to treat adult Covid patients 
    Digital Desk: India has lately launched another approach towards the treatment of Covid-19. Glenmark, a worldwide pharma business based in Mumbai, has India's first nasal spray- Nitric Oxide Nasal Spray (FabiSpray) in India.

    As part of the fast approval procedure for the first nasal spray, Glenmark acquired manufacturing and marketing authorization for Nitric Oxide Nasal Spray from India's drug authority, Drugs Controller General of India.

     "The primary objectives of the Phase 3 study in India were reached, with viral load reductions of 94 percent in 24 hours and 99 percent in 48 hours. In addition, in COVID-19 patients, nitric oxide nasal spray (NONS) was safe and well-tolerated. Therefore, Glenmark will offer NONS under the FabiSpray brand, "the official statement stated.

    The firm further claimed that when the Nitric Oxide Nasal is sprayed over nasal mucosa, it functions as a physical and chemical impediment against the virus.

    According to the official statement, "FabiSpray is prepared to destroy the COVID-19 virus in the upper airways. It has confirmed anti-microbial belongings with a direct virucidal impact on SARS-CoV-2. NONS, when sprinkled over nasal mucosa, serves as a physical and chemical barrier against the deadly virus, stopping it from incubating and extending to the lungs."

    Also Read: Opposition: Prime Minister Narendra Modi “misused” Parliament to give campaign speech

    Glenmark Pharmaceuticals Ltd's Chief Commercial Officer Robert Crockart also commented on this effective nasal spray. He said, "we are confident it will offer patients a much needed and timely therapy option."

    "As a leading pharmaceutical player, it is significant that we are an essential part of India's fight against the COVID-19 pandemic. Therefore, we are pleased to obtain regulatory clearance for Nitric Oxide Nasal Spray (FabiSpray) and launch it in collaboration with SaNOtize," he sounded.

    Dr. Monika Tandon, Senior VP and Head of Clinical Development in Glenmark Pharmaceuticals Ltd., further added that the FabiSpray outcomes from this Phase 3, double-blind, placebo-controlled test are promising.

    As per studies executed in the Utah State University USA, NONS is confirmed to destroy 99.9 % of SARS-Cov-2 virus, including Alpha, Beta, Gamma, Delta, and Epsilon variants, within two minutes.

     

    Share :

    Related News

    North East

    The Indian Army has expressed profound sorrow over the loss of its brave soldiers and extended heartfelt condolences to their families

    Regional

    The death toll rises to 10 due to the flood this year. More than 4 lakh people have been affected across 15 districts, as per the Assam State Disaster Management Authority (ASDMA) report.

    Instagram Feed

    Follow Us